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Abstract 
Background: The parasitic disease malaria remains a major global public health concern and no truly effective vac-
cine exists. One approach to the development of a malaria vaccine is to target the asexual blood stage that results 
in clinical symptoms. Most attempts have failed. New antigens such as P27A and P27 have emerged as potential 
new vaccine candidates. Multiple studies have demonstrated that antigens are more immunogenic and are better 
correlated with protection when presented on particulate delivery systems. One such particulate delivery system is 
the self-assembling protein nanoparticle (SAPN) that relies on coiled-coil domains of proteins to form stable nano-
particles. In the past we have used de novo designed amino acid domains to drive the formation of the coiled-coil 
scaffolds which present the antigenic epitopes on the particle surface.
Results: Here we use naturally occurring domains found in the tex1 protein to form the coiled-coil scaffolding of 
the nanoparticle. Thus, by engineering P27A and a new extended form of the coiled-coil domain P27 onto the N and 
C terminus of the SAPN protein monomer we have developed a particulate delivery system that effectively displays 
both antigens on a single particle that uses malaria tex1 sequences to form the nanoparticle scaffold. These particles 
are immunogenic in a murine model and induce immune responses similar to the ones observed in seropositive 
individuals in malaria endemic regions.
Conclusions: We demonstrate that our P27/P27A-SAPNs induce an immune response akin to the one in seropositive 
individuals in Burkina Faso. Since P27 is highly conserved among different Plasmodium species, these novel SAPNs 
may even provide cross-protection between Plasmodium falciparum and Plasmodium vivax the two major human 
malaria pathogens. As the SAPNs are also easy to manufacture and store they can be delivered to the population in 
need without complication thus providing a low cost malaria vaccine.
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Background
Malaria, the mosquito-borne parasitic disease caused by 
members of the Plasmodium genus, resulted in at least 
438,000 deaths worldwide in 2014 [1]. Currently, there 
is an attempt to eliminate the disease from the human 
population. Attempts at vector control, diagnosis, and 
development of pharmaceuticals have all been success-
ful in the reducing the number of cases, however, a major 
missing piece in the elimination campaign is an effective 
vaccine candidate. The current most successful vaccine 
candidate RTS,S is only about 30% protective in children 
in Sub-Saharan Africa, the most vulnerable population 
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[2, 3]. The goal of malaria elimination and the weaknesses 
of RTS,S necessitate the development of new more suc-
cessful vaccine candidates.
One of the most appealing, yet elusive, malaria vaccine 
candidates is one targeting the asexual blood stage, the 
clinical stage of the disease. Issues such as antigen poly-
morphism, lack of MHC I molecules on erythrocytes, 
and speed of erythrocyte infection all hamper the devel-
opment of an asexual blood stage vaccine [4–9]. Many 
different antigen candidates and technical approaches 
have been attempted with little to no success. These 
problems have led to the search for new potential blood 
stage antigens using different screening mechanisms 
including bioinformatic approaches.
In one such bioinformatic approach coiled-coil 
domains present in the asexual blood stage were targeted 
[10]. Coiled-coil domains are a common oligomerization 
domain in proteins known for their characteristic heptad 
repeat and stability, making them excellent choices for 
vaccine development [11]. One of the most interesting 
targets identified in this screen was P27, which showed 
complete conservation in field isolates [12]. P27 is a 27 
amino acid sequence contained on the 1103 amino acid 
trophozoite export protein (Tex1) [13]. However, P27 
was only able to activate 30% of peripheral blood mono-
nuclear cells (PBMC) from semi-immune individuals, 
leading to fears that it would not offer broad protection 
in a vaccinated diverse population. This lead to further 
screening of the Tex1 protein and the identification of 
P27A in the N-terminal portion of the protein, a region 
that was predicted to be intrinsically unstructured. 
Initial screenings demonstrated that people living in 
endemic areas had antibodies for P27A, it was immu-
nogenic in small mammal models, and antibodies raised 
against P27A were capable of inhibiting P. falciparum in 
antibody-dependent cellular inhibition parasite-growth 
assay [14]. Currently, good immunogenicity results were 
obtained in phase Ia and Ib clinical trials of P27A com-
bined with the adjuvants GLA-SE or Alhydrogel (Clini-
calTrials.gov; PACTR201310000683408; manuscript in 
preparation).
Subunit vaccines based solely on recombinant pro-
teins are generally weakly immunogenic and will most 
likely not be successful for vaccination in humans. To 
be an effective vaccine an important consideration is 
the delivery system. Several recent effective vaccine 
candidates are based on particulate delivery systems 
that are able to repetitively express antigens [15]. One 
promising delivery system is the self-assembling pro-
tein nanoparticle (SAPN) [16]. Each SAPN monomer, 
the subunit that oligomerizes to form the nanoparticle, 
contains two coiled-coil domains held together by a 
linker. Antigenic B-cell epitopes are engineered on 
either the N or C terminal ends of the gene encoding 
the monomer. In the same way T-cell epitopes can be 
added to the core leading to a vaccine candidate that is 
able to activate both the humoral and cellular branches 
of the immune system. SAPNs show great promise 
for vaccine design [15, 17–19] and many SAPN-based 
malaria vaccines have previously been developed in our 
laboratories [20–23].
Normally, the sequence of amino acids that form the 
pentameric and trimeric oligomerization domains are de 
novo designed sequences that do not have homology to 
any human proteins to minimize the possibility of induc-
ing an immune response that could be detrimental to 
the host receiving the vaccine. Here we detail the unu-
sual step in the development of a SAPN vaccine candi-
date by using a parasite native coiled-coil sequence, the 
P27 epitope from the Tex1 protein, to form part of the 
core oligomerization domains. In combination with the 
intrinsically unstructured epitope P27A, this vaccine can-
didate is immunogenic in a murine model and induces 
antibodies that are recognizing the same antigens as sera 
from seropositive individuals in Burkina Faso, a malaria 
endemic region.
Methods
Peptide sequences
Pept-P27-N (845–871):
KKRNVEEELHSLRKNYNIINEEIEEIT
Pept-P27A (223–326):
HNNNEKNISYDKNLVKQENDNKDEARGNDNMCGNYDI 
HNERGEMLDKGKSYSGDEKINTSDN AKSCSGDEKVITSD 
NGKSYDYVKNESEEQEEKENMLNNKKRS
Pept-P27-NC (846–893):
KRNVEEELHSLRKNYNIINEEIEEITKEFEKKQEQ 
VDEMILQIKNKELE
Pept-P27-C (872–893):
KEFEKKQEQVDEMILQIKNKELE
Peptide synthesis
The single antigens Pept-P27-N, Pept-P27A, Pept-
P27-NC and Pept-P27-C present in the SAPN scaffold 
were synthesized by solid-phase Fmoc chemistry using 
Applied Biosystems 431A and 433A synthesizers (Foster 
City, CA) as previously described [24]. Peptide purity was 
assessed by analytic C18 HPLC and mass spectrometry 
(MALDI-TOF, Applied Biosystems) and was higher than 
80%. All the reagents used were purchased from Fluka 
(Buchs, Switzerland) or Novabiochem (Läufelfingen, 
Switzerland).
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SAPN protein sequences
SAPN-P27-1:
MGHHHHHHASGSWEEWNAKWDEWIRAWVAWRAAWEKW 
KDDWAYWTLTWKYGELYSKLRNVEEELHSLRKNYNII 
NEEIEEITKEFEKKQEQVDEMIIQIKNKELE
SAPN-P27-2:
MGHHHHHHASLIDYNKAALSKFKERGSWQTWNAKWDV 
WSNDWNAWRARWQAWVDDWAYWTLTWKYGELYSKLR 
NVEEELHSLRKNYNIINEEIEEITKEFEKKQEQVD 
EMIIQIKNKELE
SAPN-P27A-1:
MGHHHHHHASGSWQTWNAKWDVWSNDWNAWRADW 
QAWVDDWAYWTLTWKYGELYSKLAEIERRVEANE 
R A L E E L A Q F V R A L S M Q A A E L E R R I E E I A R G 
HNNNEKNISYDKNLVKQENDNKDEARGNDNMSGNYD 
IHNERGEMLDKGKSYSGDEKINTSDNAKSSSG 
DEKVITSDNGKSYDYVKNESEEQEEKENMLNNKKRS
SAPN-P27A-2:
MGHHHHHHASYYIPHQSSLPGSWQTWNAKWDVWSNDW 
NAWRADWQAWVDDWAYWTLTWKYGELYSKLAEIERR 
VEANERALEELAQFVRALSMQAAELSEDITKYF 
RHILYISFYFILVNRARGHNNNEKNISYDKNL 
VKQENDNKDEARGNDNMSGNYDIHNERGEMLDKGKSYS 
GDEKINTSDNAKSSSGDEKVITSDNGKSYDYV 
KNESEEQEEKENMLNNKKRS
SAPN-Combo:
MGDHHHHHHHHHHAAHAAHAAHAAHAAAARG 
HNNNEKNISYDKNLVKQENDNKDEARGNDNMCGNYD 
IHNERGEMLDKGKSYSGDEKINTSDNAKSCSG 
DEKVITSDNGKSYDYVKNESEEQEEKENMLNNK 
KRSASGSAKFVAAWTLKAAASGSWEEWNAKW 
DEWRNDQNDWREDWQAWRDDWAYWTLTWRYG 
ELYSRLARIERRVEELRRLLQLIRHENRMVL 
QFVRALSMQARRLESKLRNVEEELHSLRKNYNII 
sNEEIEEITKEFEKKQEQVDEMILQIKNKELE
Gene synthesis
Codon optimized genes for E. coli were synthesized by 
GeneScript USA Inc. (Piscatway, NJ) containing the 
sequence of the constructs SAPN-P27-1, SAPN-P27-2, 
SAPN-P27A-1, SAPN-P27A-2 and SAPN-Combo. Each 
gene was cloned into a pPEP-T vector. The resulting con-
structs were transformed into Tuner (DE3) Competent 
Cells (Millipore, Billerica, MA).
Protein expression
Protein expression was carried out in Luria–Ber-
tani (LB) Broth (FisherBioReagents, Pittsburgh, PA). 
Briefly, starter cultures were grown for 16  h at 36  °C 
and inoculated at 1/100 into 1L of LB and grown at 
37  °C. At an  OD600 of 0.8 cultures were induced with 
1  mM Isopropyl-β-d-thiogalactopyranoside (IPTG) 
(FisherBioReagents, Pittsburgh, PA). Cultures were 
grown for 4  h, pelleted at 4000×  g and stored at 
−80 ºC until use.
Protein purification
Cell pellets were thawed on ice and resuspended in Imida-
zole free buffer (8 M urea, 100 mM  NaH2PO4, 20 mM Tris 
base, 5 mM tris(2-carboxyethyl)phosphine, pH 8.0), lysed 
by sonication, and centrifuged at 30,500×  g for 25  min 
to clarify the lysate. Purification was carried out on an 
ÄKTApurifier 100 (GE Healthcare, Piscataway, NJ) using 
a 5  mL HisTrap HP column (GE Healthcare, Piscataway, 
NJ). Briefly columns were equilibrated with Binding Buffer 
(8 M urea, 100 mM  NaH2PO4, 20 mM Imidazole, 20 mM 
Tris base, 5  mM tris(2-carboxyethyl)phosphine, pH 8.0), 
lysate injected, and then washed with five column volumes 
of binding buffer. Columns were then washed with 5 col-
umn volumes of high phosphate buffer (8 M Urea, 500 mM 
 NaH2PO4, 20  mM Tris base, 5  mM tris(2-carboxyethyl)
phosphine, pH 8.0), binding buffer, isopropanol wash (60% 
isopropanol, 20 mM Tris base, pH 8.0) to remove LPS [25], 
and finally Imidazole free buffer. Protein was eluted using 
a 1M Imidazole gradient. The resulting recovered protein 
was verified by a SDS-PAGE, and dialyzed overnight into 
pre-refolding buffer (8 M urea, 50 mM NaCl, 20 mM Tris, 
5% Glycerol, tris(2-carboxyethyl)phosphine, pH 8.0).
SAPN refolding
SAPNs were then allowed to refold in a stepwise manner, 
slowly removing urea and tris(2-carboxyethyl)phosphine 
and resulting in refolded SAPN in 20 mM Tris base, 5% 
glycerol, pH 8.5.
DLs
Refolding was monitored by dynamic light scattering 
using a Malvern Zetasizer Nano S (Malvern, Worcester-
shire, UK) equipped with a 633-nm laser. The hydrody-
namic diameter was determined at 25  °C. Each sample 
was run 5 times, and the average result taken.
Transmission electron microscopy
0.025 mg/mL of each sample was adsorbed onto carbon 
coated grids (Electron Microscopy Sciences Inc., Hatfield, 
PA) that were subjected to a 10 s glow discharge, washed 
with distilled water three times, and negatively stained 
with 0.5% uranyl acetate (Electron Microscopy Sciences 
Inc., Hatfield, PA). Electron micrographs were taken on 
an FEI Tecnai T12 Transmission Electron Microscope.
Human plasma
Human plasma were collected during the malaria trans-
mission season from adult donors living in Burkina Faso. 
Plasma from Swiss naive donors who had no malaria his-
tory were pooled and used as a negative control. Blood 
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was taken by venipuncture into tubes containing EDTA 
according to the ethical clearance.
Immunization
BALB/c and C3H mice (5/group) were immunized with 
10 μg of NP in PBS at the base of the tail [26] three times 
at 3 weeks interval. Mice were individually bled 10 days 
after the 2nd and 3rd immunization from the tail vein and 
corresponding sera were stored at −20  °C. Mouse stud-
ies were conducted according to the protocol VD 805.9 
approved by the state committee for animal research.
Enzyme‑linked immunosorbent assay (ELISA)
Prevalence (in humans) and titers (in mice) were deter-
mined by ELISA; antigens were diluted in PBS and used 
to coat ELISA plates. Antigen concentration for coating 
the 96-well flat plates (BD Biosciences, Allschwil, Swit-
zerland) was 1 μg/ml (50 μl) for peptides longer than 40 
residues, and 5 μg/ml for peptides shorter or equal to 40 
residues as previously described [16, 17]. Secondary Ab, 
(sheep or goat anti-human or mouse polyvalent immu-
noglobulin (G, A, M)-AP (Sigma-Aldrich, St Louis, MO, 
50 µl/well) was used at dilution indicated by the provider 
in PBS-T plus 2.5% milk. Prevalence was determined at 
plasma dilution of 1:200. Prevalence is positive when OD 
sample is ≥OD control + 3SD). Titer is defined as the last 
dilution where OD sample is ≥OD control + 3SD.
Competitive inhibition ELISA
ELISA plates were coated with the appropriate peptide as 
described above, washed and blocked. Serum samples at 
appropriate dilutions (at about 50–60% of maximum OD 
as determined by ELISA) were pre-incubated with appro-
priate competing synthetic peptides at increasing con-
centrations for 30 min at room temperature. 50 μl of the 
antibody-peptide mixture was added into the appropri-
ate wells and incubated for 1 h at room temperature in a 
humid chamber. ELISA was then completed as described 
above.
Results
SAPN design
We have already shown that SAPNs are an effective 
carrier for the pre-erythrocytic malaria antigen Cir-
cumsporozoite Protein (CSP) [20–23]. We believe the 
SAPN technology will be an excellent platform for the 
development of a malaria vaccine candidate based on 
the previously studied epitopes from the Tex1 protein. 
The prototypical SAPN design consists of a pentameric 
coiled-coil oligomerization domain linked to a trimeric 
coiled-coil oligomerization domain [16]. P27 has been 
found by prediction of its trimeric coiled-coil within 
the 27 residues. However, according to the coiled-coil 
prediction program PCOILS, the coiled-coil sequence 
extends over a span of at least 48 residues (Fig. 5). This 
prompted us to engineer a longer sequence of 50 resi-
dues containing the N-terminal P27-N and the C-ter-
minal P27-C sequences. The whole extended coiled-coil 
stretch is then called P27-NC. Remarkably, the C-ter-
minal fragment P27-C is highly conserved among many 
Plasmodium species (Fig.  5, and [14]) and thus poten-
tially providing a cross-protecting immune response. 
The SAPNs’ unique design allows P27-NC to be stably 
displayed in its native coiled-coil conformation. This 
should increase its immunogenicity and specificity and 
thus create a more effective vaccine candidate. Such 
an approach has previously been taken for the trimeric 
coiled-coil epitope of the SARS spike protein [29]. P27A 
is an intrinsically unstructured epitope, so it does not 
have the same conformation restrictions as a domain 
with a ridged shape.
Each pentameric coiled-coiled domain will self-assem-
ble with four other pentameric coiled-coiled domains, 
while each trimeric coiled-coiled domain will self-assem-
ble with two other trimeric coiled-coil domains. To sat-
isfy all of the assembly requirements 15 monomers will 
self-assemble into a structure known as a least common 
multiple unit (LCM). In a standard icosahedral structure 
four LCMs can further self-assemble into a full SAPN 
structure, meaning that 60 monomers make up each 
SAPN. However, recent biophysical studies combined 
with an analysis using viral tiling theory has shown that 
the SAPNs can possibly also assemble into higher order 
assemblies containing multiples of 60 chains per particle 
[27]. Each SAPN is predicted to contain 60 copies (or a 
multiple thereof ) of P27A and P27-NC epitopes (Fig. 2b, 
d), indicating that they are effective at repetitively dis-
playing each epitope, which is known to result in a more 
effective immune response.
Another advantage of the SAPN design is that within 
the SAPN core universal T-helper epitopes can be 
engineered that ideally lead to more effective immune 
response. These epitopes range from de novo designed 
sequences that are engineered to bind to a wide range 
of MHC II haplotypes to sequences from known infec-
tious agents that have been established to result as strong 
T-helper epitopes [28–37]. Together, the repetitive dis-
play of both epitopes (P27-NC and P27A) combined 
with the addition of the universal CD4 epitopes should 
lead to a broadly immunogenic vaccine candidate that is 
able to protect a diverse population of humans against P. 
falciparum.
We engineered several SAPNs containing either the 
extended, 50 residue-long P27-NC trimeric coiled coil 
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and/or the P27A intrinsically unstructured domain. A 
schematic representation of the five main constructs 
SAPN-P27-1, SAPN-P27-2, SAPN-P27A-1, SAPN-
P27A-2 and SAPN-Combo is shown in Fig.  1 and the 
corresponding protein sequences are listed in “Meth-
ods” section. Computational models of SAPN-P27-2 
and SAPN-Combo are displayed in Fig. 2. While the con-
structs containing only the trimeric coiled-coil epitope 
P27-NC as a B-cell epitope (SAPN-P27-1 and SAPN-
P27-2) lead to severe aggregation, the constructs with the 
intrinsically unstructured epitope P27A (SAPN-P27A-1 
and SAPN-P27A-2) formed very nice and soluble nano-
particles (Fig.  3a, b). SAPN-P27A-1 was characterized 
in 50 and 150 mM NaCl in a 20 mM phosphate buffer at 
the pH 6.8 and 7.4 and 5% glycerol. All four conditions 
resulted in satisfactory nanoparticle formation. This con-
struct was further characterized by circular dichroism for 
evaluation of secondary structure and mainly ∝-helical 
conformation was confirmed. Prior to circular dichroism 
analysis, a DLS run was taken to ensure nanoparticles 
were within expected range. For the construct SAPN-
P27A-2 even the incorporation of additional features 
such as three CD8 epitope strings predicted by NetMHC 
(YYIPHQSSL, ELSEDITKY and HILYISFYFILV—see 
also reference [38]) from the liver stage antigen 1 (LSA1) 
of the strain P. falciparum 3D7 in allowed formation of 
nice nanoparticles (Fig. 3b). We then reasoned that com-
bining the problematic P27-NC epitope with the well-
behaved P27A epitope in one single construct might 
help formation of well-shaped nanoparticles that con-
tain the trimeric coiled-coil epitope P27-NC. Indeed, the 
SAPN-Combo construct with both epitopes was structur-
ally and biophysically well-behaved (Fig. 3c, d). Thus, in 
such a construct we would be able to combine both Tex1 
derived B cell epitopes in one single protein chain form-
ing a SAPN.  
Production and refolding of SAPN‑Combo
SAPN protein monomers were expressed in Tuner (DE3) 
E. coli and purified under denaturing and reducing condi-
tions using immobilized metal chromatography. Result-
ing protein was run on SDS-Page gel to verify that the 
correct protein was purified. The primary product was in 
the expected size range of 34.3 kDa.
SAPN monomers were allowed to refold by slowly 
removing the denaturant and the reducing agent. The 
resulting product was screened by DLS to determine 
particle size. Based upon the DLS readings the refolded 
SAPN-Combo has a hydrodynamic diameter of 26.4 nm, 
which falls into the expected range for refolded SAPNs 
(Fig.  3c). The results of the DLS were further validated 
by TEM, which show SAPN-Combo has taken on par-
ticulate structure (Fig.  3d). These results demonstrate 
that we have successfully expressed and refolded the 
SAPN-Combo.
Antigenicity and immunogenicity
The prevalence of the human antibody response spe-
cific to the SAPN-Combo construct and its single com-
ponents was determined by measuring the percentage 
of adult responders living in Burkina Faso (Table 1). This 
response is similar to that originally obtained for the 
individual components Pept-P27-N and Pept-P27A (55 
and 76% with mean OD of 0.26 and 0.67, respectively) in 
terms of % prevalence and average OD [10, 14].
The immunogenicity of SAPN-Combo construct deliv-
ered in PBS buffer solution without addition of any adju-
vant was tested in BALB/c and C3H mice. End point titers 
of about 1–2  ×  106 were obtained when ELISA plates 
were coated with the homologous construct (Table  2). 
Lower titers were obtained for coating with the peptides 
Pept-P27A, Pept-P27-NC and Pept-P27-C while the Pept-
P27-N fragment is only weakly recognized. Since titers 
SAPN-P27-1
SAPN-P27-2
SAPN-P27A-1
SAPN-P27A-2
SAPN-Combo
Fig. 1 From top to bottom the schematic drawing of the constructs SAPN-P27-1, SAPN-P27-2, SAPN-P27A-1, SAPN-P27A-2 and SAPN-Combo are 
shown. Coiled coils are represented by thick boxes with the pentamer in green and the trimer in blue color. The non-coiled-coil structures are shown 
in thin boxes. The color coding is as follows: B-cell epitopes—red; CD4-epitopes—magenta; CD8-epitopes—purple; His-tag—black. The P27 B-cell 
epitope (red; N-terminal [P27-N] part solid; C-terminal [P27-C] part striped) is part of the trimeric coiled coil while the unstructured P27A (red with 
white dots) is attached at either the C-terminal or the N-terminal end of the coiled coil
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MGHHHHHHASLIDYNKAALSKFKERGSWQTWNAKWDVWSNDWNAWRARWQAWVDDWAYWTLTWKYGELYSKLRNVEEE
LHSLRKNYNIINEEIEEITKEFEKKQEQVDEMIIQIKNKELE
MGDHHHHHHHHHHAAHAAHAAHAAHAAAARGHNNNEKNISYDKNLVKQENDNKDEARGNDNMCGNYDIHNERGEMLDK
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EEWNAKWDEWRNDQNDWREDWQAWRDDWAYWTLTWRYGELYSRLARIERRVEELRRLLQLIRHENRMVLQFVRALSMQ
ARRLESKLRKNYNIINEEIEEITKEFEKKQEQVDEMIIQIKNKELE
a b
c d
Fig. 2 Molecular models of the SAPN-P27-2 (top) and SAPN-Combo (bottom) assuming icosahedral symmetry. The view is down the fivefold symme-
try axis. a, c Molecular models of the monomers; b, d molecular models of the particle. The color coding of the models is indicated in the sequences 
of the protein chains below. Monomers and particles are both drawn to size between SAPN-P27-2 and SAPN-Combo. The epitope P27-C is clearly 
more exposed within the particle than the epitope P27-N, i.e. access to P27-N is more restricted
Page 7 of 10Karch et al. J Nanobiotechnol  (2017) 15:62 
depend on the amount of each antigen bound to ELISA 
plates and its structural integrity, a better appreciation of 
the contribution of each antigen to the overall antibody 
response to SAPN-Combo is given by the determination 
of inhibition of antibody binding by single soluble anti-
gens. Total inhibition is observed in the homologous 
mode (same coating and inhibitory antigen, data not 
shown) while partial inhibition (up to 50%) is observed 
when SAPN-Combo and single antigens (Pept-P27A and 
Pept-P27-NC) are used for coating and soluble inhibitors, 
respectively (Fig. 4). Much lower inhibition was observed 
for Pept-P27-C in line with the results obtained in ELISA 
where individual antigens were used to coat the plates 
(compare Table 2). A stronger inhibition is reached if all 
three antigens are used together as inhibitors.
Discussion
Development of an effective asexual blood stage malar-
ial vaccine candidate has been difficult and fraught with 
problems. Apparently, to generate the most effective 
candidate new antigen choices as well as new delivery 
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Fig. 3 a TEM micrograph of SAPN-P27A-1; b TEM micrograph of SAPN-P27A-2; c DLS scan of the SAPN-Combo; d TEM micrograph of the SAPN-
Combo with an inset at higher resolution
Table 1 Prevalence in Burkina-Faso
Sera of 48 donors leaving in Burkina-Faso were tested in ELISA at serum dilution 
of 1:200
Antigen Mean OD % positive donors
SAPN-Combo 0.62 66
Pept-P27-NC* 0.43 62
Pept-P27-C* 0.22 62
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technologies need to be developed. Here we demon-
strated the addition of two new promising B-cell epitopes 
P27-NC and P27A from the Tex1 antigen to the SAPN 
delivery system. In particular, the P27A antigen is cur-
rently being evaluated in clinical trials as a synthetic pep-
tide (ClinicalTrials.gov; PACTR201310000683408), thus 
improving its immunogenicity by coupling to a suitable 
carrier seems to be a highly promising approach.
The humoral immune response to the two segments 
of P27-NC clearly shows the relationship of immuno-
dominant epitopes versus less immunogenic regions: 
The most prominently exposed portions of P27-NC, the 
C-terminal portion of the trimeric coiled coil (i.e. P27-
C) induces a stronger immune response compared to 
the antibody production against the N-terminal region 
P27-N (Table 2), which is more buried in the core of the 
SAPNs (see Fig. 2d). Remarkably, for the corresponding 
shorter fragment Pept-P27-C 62% is recognized by 62% 
of donor’s sera from Burkina Faso (Table  1). Since the 
P27-C is also highly conserved among many different 
Plasmodium species (Fig.  5), this is a welcome feature 
of our SAPN design as it may induce cross-protection 
among different Plasmodium species, including the most 
prominent parasites species P. falciparum and P. vivax.
One of the major advantages of our SAPN technol-
ogy is that it enables the addition of two B cell antigens, 
one on each terminus of the monomer to be displayed 
on the surface of the SAPNs. In addition, T-cell epitopes 
can be engineered into the SAPN core to be delivered 
to the antigen processing machinery of the cells. This 
unique design therefore allows for the inclusion of mul-
tiple T and B cell epitopes. In this case we included both 
P27-NC and P27A B-cell epitopes, which both have been 
established to be immunogenic in mice (P27 [10]), rab-
bits and humans (P27A [13], manuscript in prepara-
tion) in combination with a variety of CD4 and/or CD8 
epitopes. Human purified antibodies specific for P27 and 
P27A have been shown to be active in ADCI [10, 14] and 
are associated with protection in people in endemic areas 
(unpublished results). By including both P27-NC and 
P27A antigens it is likely to have a higher probability of 
inducing protective antibodies in a population at large. 
The present design has the particular advantage of being 
very immunogenic without the need of any adjuvant.
In summary, these new SAPNs represent a new vac-
cine strategy. The epitopes P27 and P27A are expressed 
primarily on the asexual blood stage of the parasite’s life 
Table 2 Serum titers of mice immunized with SAPN-Combo
Sera were collected after the 3rd immunization. Titers of individual sera were 
only determined for SAPN-Combo and Pept-P27A
a Serum pools were used for the other individual peptides
Coating antigen BALB/c C3H
SAPN-Combo 1.1 +/− 0 X 106 2.0 ± 1.0 × 106
Pept-P27A 8.3 ± 3.7 X 105 1.3 ± 0.62 × 106
Pept-P27-NCa 8.1 X 104 2.4 × 105
Pept-P27-Ca 2.7 X 104 8.4 × 104
Pept-P27-Na ≤5.4 X 103 ≤5.4 × 103
Fig. 4 ELISA plates were coated with SAPN-Combo and antibody 
binding was inhibited by soluble antigen as indicates in the figure  
(a BALB/c; b C3H)
 a  d   a  d   a  d   a  d   a  d   a  d   a  d 
SAPN-ComboKLRNVEEELHSLRKNYNIINEEIEEITKEFEKKQEQVDEMILQIKNKELE
P. falciparum KKRNVEEELHSLRKNYNIINEEIEEITKEFEKKQEQVDEMILQIKNKELE
P. vivax KKQNAEKELSVLKKNYDAMSEEIEEITKEFEKKQEQVDEMIIQIKNKEFE
P. knowlesi KKKNAENELSILKKNYDAMSEEIEEITKEFEKKQEQVDEMIIQIKNKELE
P. malariae KKKNVENELSSLRKNYDAMSEEIEEITKEFEKKQEQIDEMIVQIKNKELE
P. berghei KKKDVEDELINLKSSYNSMSEEIEEITKEFEKKQEQIDEMILQIKNKEME
Similarity * ::.*.**  *:..*: :.****************:****:******:* 
Fig. 5 Sequence conservation of P27-N and P27-C in SAPN-Combo 
compared to other important Plasmodium strains multiple sequence 
alignment (CLUSTAL O v1.2.4). Completely conserved residues among 
all strains are shown in black and bold. The sequences are the follow-
ing from top to bottom: XP_966024.1—Plasmodium falciparum 3D7; 
SCO68358.1—Plasmodium vivax; XP_002261647.1—Plasmodium 
knowlesi; SBS87522.1—Plasmodium malariae; XP_679242.1—Plasmo-
dium berghei ANKA. The residues that are predicted to have a higher 
coiled-coil propensity than 0.9 for the SAPN-Combo are highlighted 
in yellow (PCOILS v1.0.1). The coiled-coil heptad-repeat with the core 
positions (a) and (d) is indicated above the sequences
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cycle, while CSP is expressed on the pre-erythrocytic 
stage. A CSP based vaccine will only prevent infection 
before clinical symptoms develop. An asexual blood 
stage vaccine will actually help deal with preventing para-
sitemia from further developing and reducing clinical 
symptoms. As both approaches continue to be developed 
they eventually can be admixed to generate a vaccine 
candidate that prevents the initial infection, and can 
eventually prevent any breakthrough infection.
Conclusion
Here we have demonstrated that SAPNs induce an 
immune response akin to the one in seropositive indi-
viduals in Burkina Faso. The SAPNs described in this 
manuscript represent a key improvement over previous 
designs. Modification of the nanoparticles allowed P27 
to be presented, which was not possible with the first 
designs of the SAPNs. Since P27 is highly conserved, 
this might even provide cross-protection among differ-
ent Plasmodium species. If confirmed in human clinical 
trials, it would allow the development of a robust vac-
cine easy to manufacture, store and deliver to the needed 
population. These vaccine characteristics have been 
and remain the “holy grail” of vaccine development and 
formulation.
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